HBV-ANTISENSE-HEMMER

Patent europeic · EP2512491 · Stritgà

Inscripziun en il register

Numer da publicaziun
EP2512491
Numer da la dumonda
EP10824199
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
Stritgà
Scrittira da patent
Concedì
Annunzià
15-10-2010
Publitgà
24-10-2012
Concedì
11-10-2017
Stritgà
22-04-2020
Motiv
Revocà en la procedura d’opposiziun
Classas IPC
A61K 31/7115 (2006.01)
A61K 31/7125 (2006.01)
A61P 1/16 (2006.01)
A61P 31/20 (2006.01)
Prioritad
US 252380 P 16.10.2009
Dumonda PCT
PCT/US2010/052911 15.10.2010
Publicaziun PCT
WO2011/047312 21.04.2011
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 22-04-2020

    Midada

    Published in Swissreg on 22.04.2020

  2. 25-10-2017

    Represchentant inscrit

    Representative
    E. Blum & Co. AG, Patent- und Markenanwälte VSP, Vorderberg 11, 8044 Zürich

    Published in Swissreg on 25.10.2017

  3. 11-10-2017

    Concedì

    Published in Swissreg on 11.10.2017

Partidas

Possessur

Glaxo Group Limited

980 Great West Road, Brentford, Middlesex TW8 9GS, GB

Represchentant

E. Blum & Co. AG

E. Blum & Co. AG Patent- und Markenanwälte VSP

Vorderberg 11, 8044 Zürich

Inventur

HAMATAKE, Robert

Research Triangle Park, North Carolina 27709, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.